CoChat

Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid β Protein Antibody-Coated Nanoparticles

Open access
Poduslo, Joseph F., Hultman, Kristi L., Curran, Geoffry L., Preboske, Gregory M., Chamberlain, Ryan, Marjańska, Małgorzata, Garwood, Michael, Jack, Clifford R., Wengenack, Thomas M. · 2011 · Journal of Neuropathology & Experimental Neurology
Cited by 64

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The relevance of cerebral amyloid angiopathy (CAA) to the pathogenesis of Alzheimer disease (AD) and dementia in general emphasizes the importance of developing novel targeting approaches for detecting and treating cerebrovascular amyloid (CVA) deposits. We developed a nanoparticle-based technology that uses a monoclonal antibody against fibrillar human amyloid-β42 that is surface coated onto a functionalized phospholipid monolayer. We demonstrate that this conjugated nanoparticle binds to CVA deposits in arterioles of AD transgenic mice (Tg2576) after infusion into the external carotid artery using 3 different approaches. The first 2 approaches use a blood vessel enrichment of homogenized brain and a leptomeningeal vessel preparation from thin tangential brain slices from the surface of the cerebral cortex. Targeting of CVA by the antibody-coated nanoparticle was visualized using fluorescent lissamine rhodamine-labeled phospholipids in the nanoparticles, which were compared with fluorescent staining of the endothelial cells and amyloid deposits using confocal laser scanning microscopy. The third approach used high-field strength magnetic resonance imaging of antibody-coated iron oxide nanoparticles after infusion into the external carotid artery. Dark foci of contrast enhancement in cortical arterioles were observed in T2*-weighted images of ex vivo AD mouse brains that correlated histologically with CVA deposits. The targeting ability of these nanoparticles to CVA provides opportunities for the prevention and treatment of CAA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e318225038c

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 64

Metadata

Authors
Poduslo, J. F., Hultman, K. L., Curran, G. L., Preboske, G. M., Chamberlain, R., Marjańska, M., Garwood, M., Jack, C. R., & Wengenack, T. M.
Venue
Journal of Neuropathology & Experimental Neurology
Published
2011-08
Volume
70
Issue
8
Pages
653-661
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W2315214392
Cited by
64
References
5
FWCI
3.27
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid β Protein Antibody-Coated Nanoparticles. https://app.cochat.ai/papers/10.1097/nen.0b013e318225038c
The paper
Poduslo, J. F., Hultman, K. L., Curran, G. L., Preboske, G. M., Chamberlain, R., Marjańska, M., Garwood, M., Jack, C. R., & Wengenack, T. M. (2011). Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid β Protein Antibody-Coated Nanoparticles. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e318225038c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.